Synthroid

Manufacturer
AbbVie Inc.
Effective date
2024-02-20
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1537
Source
full-release
Hydrated at
2026-05-31 21:00:23

Label at a glance#

ProductSynthroid
Active ingredientLEVOTHYROXINE SODIUM
Label structure30 sections

Boxed warning

Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life - threatening manifestations of toxicity, particularly when given in association with sympathomimetic ...

Indications and uses

Hypothyroidism SYNTHROID is indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid -Stimulating Hormone, TSH) Suppression SYNTHROID is indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine ...

Dosage and administration

Administer SYNTHROID as a single daily dose, on an empty stomach, one-half to one hour before breakfast. Administer SYNTHROID at least 4 hours before or after drugs known to interfere with SYNTHROID absorption [see Drug Interactions ( 7.1 ) ] . Evaluate the need for dosage adjustments when regularly administering within one hour of certain foods that may affect SYNTHROID absorption [see Dosage and Administration (...

Storage and handling

How Supplied SYNTHROID (levothyroxine sodium, USP) tablets are supplied as follows ( Table 11 ): Table 11: SYNTHROID Tablet Presentations Strength (mcg) Color/Shape Tablet Markings NDC# for bottles of 90 NDC # for bottles of 1000 NDC # for unit dose cartons of 100 25 Orange/Round “SYNTHROID” and “25” 0074-4341-90 0074-4341-19 -- 50 White/Round “SYNTHROID” and “50” 0074-4552-90 0074-4552-19 0074-4552-11 75 Violet/R...

Label contents#

Full prescribing information#

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

BOXED WARNING SECTION

Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.

In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6), Drug Interactions (7.7), and Overdosage (10)].

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Hypothyroidism

SYNTHROID is indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression

SYNTHROID is indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Limitations of Use

  • SYNTHROID is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with SYNTHROID may induce hyperthyroidism [see Warnings and Precautions ( 5.1 )]. 
  • SYNTHROID is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 Important Administration Instructions

SPL UNCLASSIFIED SECTION

Administer SYNTHROID as a single daily dose, on an empty stomach, one-half to one hour before breakfast.

Administer SYNTHROID at least 4 hours before or after drugs known to interfere with SYNTHROID absorption [see Drug Interactions ( 7.1 ) ].

Evaluate the need for dosage adjustments when regularly administering within one hour of certain foods that may affect SYNTHROID absorption [see Dosage and Administration ( 2.2 and 2.3 ), Drug Interactions ( 7.9 ) , and Clinical Pharmacology ( 12.3 ) ].

Administer SYNTHROID to pediatric patients who cannot swallow intact tablets by crushing the tablet, suspending the freshly crushed tablet in a small amount (5 to 10 mL) of water and immediately administering the suspension by spoon or dropper. Ensure the patient ingests the full amount of the suspension. Do not store the suspension. Do not administer in foods that decrease absorption of SYNTHROID, such as soybean-based infant formula [see Drug Interactions ( 7.9 ) ].

2.2 Important Considerations for Dosing

SPL UNCLASSIFIED SECTION

The dosage of SYNTHROID for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food and the specific nature of the condition being treated [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5 ), and Drug Interactions ( 7 )]. Dosing must be individualized to account for these factors and dosage adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see Dosage and Administration ( 2.4 )]. 

For adult patients with primary hypothyroidism, titrate until the patient is clinically euthyroid and the serum TSH returns to normal [see Dosage and Administration ( 2.3 )].

For secondary or tertiary hypothyroidism, serum TSH is not a reliable measure of SYNTHROID dosage adequacy and should not be used to monitor therapy. Use the serum free-T4 level to titrate SYNTHROID dosing until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range [see Dosage and Administration ( 2.3 )].

Inquire whether patients are taking biotin or biotin-containing supplements. If so, advise them to stop biotin supplementation at least 2 days before assessing TSH and/or T4 levels [see Dosage and Administration ( 2.4 ) and Drug Interactions ( 7.10 )].

The peak therapeutic effect of a given dose of SYNTHROID may not be attained for 4 to 6 weeks.

2.4 Monitoring TSH and/or Thyroxine (T4) Levels

SPL UNCLASSIFIED SECTION

Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation.

Biotin supplementation may interfere with immunoassays for TSH, T4, and T3, resulting in erroneous thyroid hormone test results. Stop biotin and biotin-containing supplements for at least 2 days before assessing TSH and/or T4 levels [see Drug Interactions ( 7.10 )].  

Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of SYNTHROID may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.

Adults

In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dosage. In patients on a stable and appropriate replacement dosage, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient’s clinical status.

Pediatric Patients

In patients with hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in pediatric patients as follows: 2 and 4 weeks after the initiation of treatment, 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dosage stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals.

The general aim of therapy is to normalize the serum TSH level. TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of SYNTHROID therapy and/or of the serum TSH to decrease below 20 mIU per liter within 4 weeks may indicate the patient is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of SYNTHROID [see Warnings and Precautions ( 5.1 )   and Use in Specific Populations ( 8.4 )]. 

Secondary and Tertiary Hypothyroidism

Monitor serum free-T4 levels and maintain in the upper half of the normal range in these patients.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

SYNTHROID tablets are available as follows (Table 4):

Table 4: SYNTHROID Tablet Strengths and Identifying Features
Tablet Strength Tablet Color/Shape Tablet Markings
25 mcgOrange/Round “SYNTHROID” and “25”
50 mcgWhite/Round “SYNTHROID” and “50”
75 mcgViolet/Round “SYNTHROID” and “75”
88 mcgOlive/Round “SYNTHROID” and “88”
100 mcgYellow/Round“SYNTHROID” and “100”
112 mcgRose/Round“SYNTHROID” and “112”
125 mcgBrown/Round“SYNTHROID” and “125”
137 mcgTurquoise/Round“SYNTHROID” and “137”
150 mcgBlue/Round“SYNTHROID” and “150”
175 mcgLilac/Round“SYNTHROID” and “175”
200 mcgPink/Round“SYNTHROID” and “200”
300 mcgGreen/Round “SYNTHROID” and “300”

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

SYNTHROID is contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions ( 5.4 ) ].

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.2 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease

SPL UNCLASSIFIED SECTION

Over-treatment with levothyroxine may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate SYNTHROID therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease [see Dosage and Administration ( 2.3 ) and Use in Specific Populations ( 8.5 ) ].

Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive SYNTHROID therapy. Monitor patients receiving concomitant SYNTHROID and sympathomimetic agents for signs and symptoms of coronary insufficiency.

If cardiac symptoms develop or worsen, reduce the SYNTHROID dose or withhold for one week and restart at a lower dose.

5.3 Myxedema Coma

SPL UNCLASSIFIED SECTION

Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma.

5.4 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency

SPL UNCLASSIFIED SECTION

Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with SYNTHROID [see Contraindications ( 4 )].

5.5 Worsening of Diabetic Control

SPL UNCLASSIFIED SECTION

Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing SYNTHROID [see Drug Interactions ( 7.2 ) ].

5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement

SPL UNCLASSIFIED SECTION

Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels. Administer the minimum dose of SYNTHROID that achieves the desired clinical and biochemical response to mitigate this risk.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Adverse reactions associated with SYNTHROID therapy are primarily those of hyperthyroidism due to therapeutic overdosage [see Warnings and Precautions ( 5 ) and Overdosage ( 10 ) ]. They include the following:

  • General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating
  • Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia
  • Musculoskeletal: tremors, muscle weakness, muscle spasm
  • Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest
  • Respiratory: dyspnea
  • Gastrointestinal: diarrhea, vomiting, abdominal cramps, elevations in liver function tests
  • Dermatologic: hair loss, flushing, rash
  • Endocrine: decreased bone mineral density
  • Reproductive: menstrual irregularities, impaired fertility

Seizures have been reported rarely with the institution of levothyroxine therapy.

Adverse Reactions in Pediatric Patients

Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in pediatric patients receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants who have not undergone complete closure of the fontanelles, and in premature closure of the epiphyses in pediatric patients still experiencing growth with resultant compromised adult height.

Hypersensitivity Reactions

Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness, and wheezing. Hypersensitivity to levothyroxine itself is not known to occur.

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics

SPL UNCLASSIFIED SECTION

Many drugs can exert effects on thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to SYNTHROID (Tables 5 to 8).

Table 5. Drugs That May Decrease T4 Absorption (Hypothyroidism)
Potential impact: Concurrent use may reduce the efficacy of SYNTHROID by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.
Drug or Drug ClassEffect
Phosphate Binders
   (e.g., calcium carbonate, ferrous
   sulfate, sevelamer, lanthanum)
Phosphate binders may bind to levothyroxine. Administer SYNTHROID at least 4 hours apart from these agents.
OrlistatMonitor patients treated concomitantly with orlistat and SYNTHROID for changes in thyroid function.
Bile Acid Sequestrants
   (e.g., colesevelam, cholestyramine,
   colestipol)
Ion Exchange Resins
   (e.g., Kayexalate)
Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer SYNTHROID at least 4 hours prior to these drugs or monitor TSH levels.
Proton Pump Inhibitors
Sucralfate
Antacids
   (e.g., aluminum & magnesium
   hydroxides, simethicone)
Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption. Monitor patients appropriately.
Table 6. Drugs That May Alter T4 and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism)
Drug or Drug Class Effect
Clofibrate
Estrogen-containing oral contraceptives
Estrogens (oral)
Heroin / Methadone
5-Fluorouracil
Mitotane
Tamoxifen
These drugs may increase serum thyroxine-binding globulin (TBG) concentration.
Androgens / Anabolic Steroids
Asparaginase
Glucocorticoids
Slow-Release Nicotinic Acid
These drugs may decrease serum TBG concentration.
Potential impact (below): Administration of these agents with SYNTHROID results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations.
Salicylates (> 2 g/day)Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%.
Other drugs:
Carbamazepine
Furosemide (> 80 mg IV)
Heparin
Hydantoins
Non-Steroidal Anti-inflammatory Drugs
- Fenamates
These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters.
Table 7. Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism)
Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased SYNTHROID requirements.
Drug or Drug ClassEffect
Phenobarbital
Rifampin
Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5’-diphospho-glucuronosyltransferase (UGT) and leads to lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine.
Table 8. Drugs That May Decrease Conversion of T4 to T3
Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased.
Drug or Drug ClassEffect
Beta-adrenergic antagonists
(e.g., Propranolol > 160 mg/day)
In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when a hypothyroid patient is converted to the euthyroid state.
Glucocorticoids
(e.g., Dexamethasone > 4 mg/day)
Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (See above).
Other drugs:
Amiodarone
Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients.

7.2 Antidiabetic Therapy

SPL UNCLASSIFIED SECTION

Addition of SYNTHROID therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued [see Warnings and Precautions ( 5.5 ) ].

7.3 Oral Anticoagulants

SPL UNCLASSIFIED SECTION

SYNTHROID increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the SYNTHROID dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments.

7.4 Digitalis Glycosides

SPL UNCLASSIFIED SECTION

SYNTHROID may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may decrease when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.

7.5 Antidepressant Therapy

SPL UNCLASSIFIED SECTION

Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and SYNTHROID may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. SYNTHROID may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on SYNTHROID may result in increased SYNTHROID requirements.

7.6 Ketamine

SPL UNCLASSIFIED SECTION

Concurrent use of ketamine and SYNTHROID may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients.

7.7 Sympathomimetics

SPL UNCLASSIFIED SECTION

Concurrent use of sympathomimetics and SYNTHROID may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.

7.8 Tyrosine-Kinase Inhibitors

SPL UNCLASSIFIED SECTION

Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients.

7.9 Drug-Food Interactions

SPL UNCLASSIFIED SECTION

Consumption of certain foods may affect SYNTHROID absorption thereby necessitating adjustments in dosing [see Dosage and Administration ( 2.1 ) ]. Soybean flour, cottonseed meal, walnuts, and dietary fiber may bind and decrease the absorption of SYNTHROID from the gastrointestinal tract. Grapefruit juice may delay the absorption of levothyroxine and reduce its bioavailability.

7.10 Drug-Laboratory Test Interactions

DRUG & OR LABORATORY TEST INTERACTIONS SECTION

Thyroxine-binding Globulin (TBG)

Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free-T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentration. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens, and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.

Biotin

Biotin supplementation is known to interfere with thyroid hormone immunoassays that are based on a biotin and streptavidin interaction, which may result in erroneous thyroid hormone test results. Stop biotin and biotin-containing supplements for at least 2 days prior to thyroid testing.  

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary

The clinical experience, including data from postmarketing studies, in pregnant women treated with oral levothyroxine to maintain euthyroid state have not reported increased rates of major birth defects, miscarriages, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. Since TSH levels may increase during pregnancy, TSH should be monitored and SYNTHROID dosage adjusted during pregnancy (see Clinical Considerations). Animal reproductive studies have not been conducted with levothyroxine sodium. SYNTHROID should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. 

Clinical Considerations

Disease-Associated Maternal and/or Embryo/Fetal Risk

Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre-eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development.

Dose Adjustments During Pregnancy and the Postpartum Period

Pregnancy may increase SYNTHROID requirements. Serum TSH levels should be monitored and the SYNTHROID dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the SYNTHROID dosage should return to the pre-pregnancy dose immediately after delivery [see Dosage and Administration ( 2.3 ) ].

8.2 Lactation

LACTATION SECTION

Risk Summary

Published studies report that levothyroxine is present in human milk following the administration of oral levothyroxine. No adverse effects on the breastfed infant have been reported and there is no information on the effects of levothyroxine on milk production. Adequate levothyroxine treatment during lactation may normalize milk production in hypothyroid lactating mothers with low milk supply. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SYNTHROID and any potential adverse effects on the breastfed infant from SYNTHROID or from the underlying maternal condition.

8.4 Pediatric Use

PEDIATRIC USE SECTION

SYNTHROID is indicated in patients from birth to less than 17 years of age:

  • As a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
  • As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on cognitive development as well as on overall physical growth and maturation. Therefore, initiate SYNTHROID therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients [ see Warnings and Precautions ( 5.1 ) ].

Closely monitor infants during the first 2 weeks of SYNTHROID therapy for cardiac overload and arrhythmias.

8.5 Geriatric Use

GERIATRIC USE SECTION

Because of the increased prevalence of cardiovascular disease among the elderly, initiate SYNTHROID at less than the full replacement dose [see Dosage and Administration ( 2.3 ) and Warnings and Precautions ( 5.2 ) ]. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly.

10 OVERDOSAGE

OVERDOSAGE SECTION

The signs and symptoms of overdosage are those of hyperthyroidism [see Warnings and Precautions ( 5 ) and Adverse Reactions ( 6 ) ]. In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures occurred in a 3-year-old child ingesting 3.6 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium.

Reduce the SYNTHROID dosage or discontinue temporarily if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient’s medical status.

For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.

11 DESCRIPTION

DESCRIPTION SECTION

SYNTHROID (levothyroxine sodium tablets, USP) is L-thyroxine (T4) and contains synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt. Synthetic T4 is chemically identical to that produced in the human thyroid gland. Levothyroxine (T4) sodium has an empirical formula of C15H10I4N NaO4• H2O, molecular weight of 798.86 (anhydrous), and structural formula as shown:

SYNTHROID (levothyroxine sodium tablets, USP) contain synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is chemically id...SYNTHROID (levothyroxine sodium tablets, USP) contain synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is chemically id...

SYNTHROID tablets for oral administration are supplied in the following strengths: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg. Each SYNTHROID tablet contains the inactive ingredients acacia, confectioner's sugar (contains corn starch), lactose monohydrate, magnesium stearate, povidone, and talc. SYNTHROID tablets contain no ingredients made from a gluten-containing grain (wheat, barley, or rye). Each tablet strength meets USP Dissolution Test 3. Table 9 provides a listing of the color additives by tablet strength:

Table 9: SYNTHROID Tablet Color Additives
Strength
(mcg)
Color additive(s)
25FD&C Yellow No. 6 Aluminum Lake*
50None
75FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake
88FD&C Blue No. 1 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake*, D&C Yellow No. 10 Aluminum Lake
100D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake*
112D&C Red No. 27 & 30 Aluminum Lake
125FD&C Yellow No. 6 Aluminum Lake*, FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake
137FD&C Blue No. 1 Aluminum Lake
150FD&C Blue No. 2 Aluminum Lake
175FD&C Blue No. 1 Aluminum Lake, D&C Red No. 27 & 30 Aluminum Lake
200FD&C Red No. 40 Aluminum Lake
300D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake*, FD&C Blue No. 1 Aluminum Lake
* Note – FD&C Yellow No. 6 is orange in color.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.

The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

Oral levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

Absorption

Absorption of orally administered T4 from the gastrointestinal tract ranges from 40% to 80%. The majority of the SYNTHROID dose is absorbed from the jejunum and upper ileum. The relative bioavailability of SYNTHROID tablets, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 93%. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. Dietary fiber decreases bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption [see Drug Interactions ( 7 ) ].

Distribution

Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins [see Drug Interactions ( 7 ) ]. Thyroid hormones do not readily cross the placental barrier [see Use in Specific Populations ( 8.1 ) ].

Elimination

Metabolism

T4 is slowly eliminated (see Table 10). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80% of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.

Excretion

Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age.

Table 10. Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients
HormoneRatio in ThyroglobulinBiologic Potencyt1/2 (days)Protein Binding (%)*
Levothyroxine (T4)10 - 2016-7**99.96
Liothyronine (T3)14≤ 299.5
* Includes TBG, TBPA, and TBA
** 3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term carcinogenicity studies in animals to evaluate the carcinogenic potential of levothyroxine have not been performed. Studies to evaluate mutagenic potential and animal fertility have not been performed.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

How Supplied

SYNTHROID (levothyroxine sodium, USP) tablets are supplied as follows (Table 11):

Table 11: SYNTHROID Tablet Presentations
Strength
(mcg)
Color/ShapeTablet
Markings
NDC# for
bottles of 90
NDC # for
bottles of 1000
NDC # for
unit dose

cartons of 100
25Orange/Round“SYNTHROID”
and “25”
0074-4341-900074-4341-19--
50White/Round“SYNTHROID”
and “50”
0074-4552-900074-4552-190074-4552-11
75Violet/Round“SYNTHROID”
and “75”
0074-5182-900074-5182-190074-5182-11
88Olive/Round“SYNTHROID”
and “88”
0074-6594-900074-6594-19--
100Yellow/Round“SYNTHROID”
and “100”
0074-6624-900074-6624-190074-6624-11
112Rose/Round“SYNTHROID”
and “112”
0074-9296-900074-9296-19--
125Brown/Round“SYNTHROID”
and “125”
0074-7068-900074-7068-190074-7068-11
137Turquoise/Round“SYNTHROID”
and “137”
0074-3727-900074-3727-19--
150Blue/Round“SYNTHROID”
and “150”
0074-7069-900074-7069-190074-7069-11
175Lilac/Round“SYNTHROID”
and “175”
0074-7070-900074-7070-19--
200Pink/Round“SYNTHROID”
and “200”
0074-7148-900074-7148-190074-7148-11
300Green/Round“SYNTHROID”
and “300”
0074-7149-900074-7149-19--

Storage and Handling

Store SYNTHROID at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (see USP Controlled Room Temperature).

SYNTHROID tablets should be protected from light and moisture.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Inform the patient of the following information to aid in the safe and effective use of SYNTHROID:

Dosing and Administration

  • Instruct patients to take SYNTHROID only as directed by their healthcare provider.
  • Instruct patients to take SYNTHROID as a single dose, preferably on an empty stomach, one-half to one hour before breakfast.
  • Inform patients that agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine. Instruct patients not to take SYNTHROID tablets within 4 hours of these agents.
  • Instruct patients to notify their healthcare provider if they are pregnant or breastfeeding or are thinking of becoming pregnant while taking SYNTHROID.

Important Information

  • Inform patients that it may take several weeks before they notice an improvement in symptoms.
  • Inform patients that the levothyroxine in SYNTHROID is intended to replace a hormone that is normally produced by the thyroid gland. Generally, replacement therapy is to be taken for life.
  • Inform patients that SYNTHROID should not be used as a primary or adjunctive therapy in a weight control program.
  • Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over-the-counter preparations.
  • Instruct patients to discontinue biotin or any biotin-containing supplements for at least 2 days before thyroid function testing is conducted.
  • Instruct patients to notify their physician of any other medical conditions they may have, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems, as the dose of medications used to control these other conditions may need to be adjusted while they are taking SYNTHROID. If they have diabetes, instruct patients to monitor their blood and/or urinary glucose levels as directed by their physician and immediately report any changes to their physician. If patients are taking anticoagulants, their clotting status should be checked frequently.
  • Instruct patients to notify their physician or dentist that they are taking SYNTHROID prior to any surgery.

Adverse Reactions

  • Instruct patients to notify their healthcare provider if they experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event.
  • Inform patients that partial hair loss may occur rarely during the first few months of SYNTHROID therapy, but this is usually temporary.

© 2024 AbbVie Inc. All rights reserved.

SYNTHROID and its design are trademarks of AbbVie Inc. 

AbbVie Inc.

North Chicago, IL 60064 U.S.A.

20083657

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-4552-11

Synthroid®

Levothyroxine Sodium
Tablets, USP

50 mcg (0.05 mg)

100 Tablets

THIS PACKAGE FOR
HOUSEHOLDS WITHOUT
YOUNG CHILDREN

Rx only abbvie 

NDC 0074-4552-11 Synthroid® Levothyroxine Sodium Tablets, USP 50 mcg (0.05 mg) 100 Tablets THIS PACKAGE FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN Rx only abbvieNDC 0074-4552-11 Synthroid® Levothyroxine Sodium Tablets, USP 50 mcg (0.05 mg) 100 Tablets THIS PACKAGE FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-6624-11

Synthroid®

Levothyroxine Sodium
Tablets, USP

100 mcg (0.1 mg)

100 Tablets

THIS PACKAGE FOR
HOUSEHOLDS WITHOUT
YOUNG CHILDREN

Rx only abbvie 

NDC 0074-6624-11 Synthroid® Levothyroxine Sodium Tablets, USP 100 mcg (0.1 mg) 100 Tablets THIS PACKAGE FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN Rx only abbvieNDC 0074-6624-11 Synthroid® Levothyroxine Sodium Tablets, USP 100 mcg (0.1 mg) 100 Tablets THIS PACKAGE FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-7148-11

Synthroid®

Levothyroxine Sodium
Tablets, USP

200 mcg (0.2 mg)

100 Tablets

THIS PACKAGE FOR
HOUSEHOLDS WITHOUT
YOUNG CHILDREN

Rx only abbvie 

NDC 0074-7148-11 Synthroid® Levothyroxine Sodium Tablets, USP 200 mcg (0.2 mg) 100 Tablets THIS PACKAGE FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN Rx only abbvieNDC 0074-7148-11 Synthroid® Levothyroxine Sodium Tablets, USP 200 mcg (0.2 mg) 100 Tablets THIS PACKAGE FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-3727-90

Synthroid®

Levothyroxine
Sodium Tablets,
USP

137 mcg
(0.137 mg)

90 Tablets

Rx only abbvie 

NDC 0074-3727-90 Synthroid® Levothyroxine Sodium Tablets, USP 137 mcg (0.137 mg) 90 Tablets Rx only abbvieNDC 0074-3727-90 Synthroid® Levothyroxine Sodium Tablets, USP 137 mcg (0.137 mg) 90 Tablets Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-4341-19

Synthroid®

Levothyroxine
Sodium Tablets,
USP

25 mcg
(0.025 mg)

1000 Tablets

Rx only abbvie

NDC 0074-4341-19 Synthroid® Levothyroxine Sodium Tablets, USP 25 mcg (0.025 mg) 1000 Tablets Rx only abbvieNDC 0074-4341-19 Synthroid® Levothyroxine Sodium Tablets, USP 25 mcg (0.025 mg) 1000 Tablets Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-5182-19

Synthroid®

Levothyroxine
Sodium Tablets,
USP

75 mcg
(0.075 mg)

1000 Tablets

Rx only abbvie 

NDC 0074-5182-19 Synthroid® Levothyroxine Sodium Tablets, USP 75 mcg (0.075 mg) 1000 Tablets Rx only abbvieNDC 0074-5182-19 Synthroid® Levothyroxine Sodium Tablets, USP 75 mcg (0.075 mg) 1000 Tablets Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-6594-90

Synthroid®

Levothyroxine
Sodium Tablets,
USP

88 mcg
(0.088 mg)

90 Tablets

Rx only abbvie 

NDC 0074-6594-90 Synthroid® Levothyroxine Sodium Tablets, USP 88 mcg (0.088 mg) 90 Tablets Rx only abbvieNDC 0074-6594-90 Synthroid® Levothyroxine Sodium Tablets, USP 88 mcg (0.088 mg) 90 Tablets Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-7068-19

Synthroid®

Levothyroxine
Sodium Tablets,
USP

125 mcg
(0.125 mg)

1000 Tablets

Rx only abbvie 

NDC 0074-7068-19 Synthroid® Levothyroxine Sodium Tablets, USP 125 mcg (0.125 mg) 1000 Tablets Rx only abbvieNDC 0074-7068-19 Synthroid® Levothyroxine Sodium Tablets, USP 125 mcg (0.125 mg) 1000 Tablets Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-7069-90

Synthroid®

Levothyroxine
Sodium Tablets,
USP

150 mcg
(0.15 mg)

90 Tablets

Rx only abbvie 

NDC 0074-7069-90 Synthroid® Levothyroxine Sodium Tablets, USP 150 mcg (0.15 mg) 90 Tablets Rx only abbvieNDC 0074-7069-90 Synthroid® Levothyroxine Sodium Tablets, USP 150 mcg (0.15 mg) 90 Tablets Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-7070-19

Synthroid®

Levothyroxine
Sodium Tablets,
USP

175 mcg
(0.175 mg)

1000 Tablets

Rx only abbvie 

NDC 0074-7070-19 Synthroid® Levothyroxine Sodium Tablets, USP 175 mcg (0.175 mg) 1000 Tablets Rx only abbvieNDC 0074-7070-19 Synthroid® Levothyroxine Sodium Tablets, USP 175 mcg (0.175 mg) 1000 Tablets Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-7149-90

Synthroid®

Levothyroxine
Sodium Tablets,
USP

300 mcg
(0.3 mg)

90 Tablets

Rx only abbvie 

NDC 0074-7149-90 Synthroid® Levothyroxine Sodium Tablets, USP 300 mcg (0.3 mg) 90 Tablets Rx only abbvieNDC 0074-7149-90 Synthroid® Levothyroxine Sodium Tablets, USP 300 mcg (0.3 mg) 90 Tablets Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-9296-19

Synthroid®

Levothyroxine
Sodium Tablets,
USP

112 mcg
(0.112 mg)

1000 Tablets

Rx only abbvie 

NDC 0074-9296-19 Synthroid® Levothyroxine Sodium Tablets, USP 112 mcg (0.112 mg) 1000 Tablets Rx only abbvieNDC 0074-9296-19 Synthroid® Levothyroxine Sodium Tablets, USP 112 mcg (0.112 mg) 1000 Tablets Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-4552-90

Synthroid®

Levothyroxine
Sodium Tablets,
USP

50 mcg
(0.05 mg) 

90 Tablets

Rx only abbvie 

NDC 0074-4552-90 Synthroid® Levothyroxine Sodium Tablets, USP 50 mcg (0.05 mg) 90 Tablets Rx only abbvieNDC 0074-4552-90 Synthroid® Levothyroxine Sodium Tablets, USP 50 mcg (0.05 mg) 90 Tablets Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-7148-90

Synthroid®

Levothyroxine
Sodium Tablets,
USP

200 mcg
(0.2 mg) 

90 Tablets

Rx only abbvie 

NDC 0074-7148-90 Synthroid® Levothyroxine Sodium Tablets, USP 200 mcg (0.2 mg) 90 Tablets Rx only abbvieNDC 0074-7148-90 Synthroid® Levothyroxine Sodium Tablets, USP 200 mcg (0.2 mg) 90 Tablets Rx only abbvie

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0074-6624-90

Synthroid®

Levothyroxine
Sodium Tablets,
USP

100 mcg
(0.1 mg) 

90 Tablets

Rx only abbvie 

NDC 0074-6624-90 Synthroid® Levothyroxine Sodium Tablets, USP 100 mcg (0.1 mg) 90 Tablets Rx only abbvieNDC 0074-6624-90 Synthroid® Levothyroxine Sodium Tablets, USP 100 mcg (0.1 mg) 90 Tablets Rx only abbvie

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
892246levothyroxine sodium 100 MCG Oral TabletPSN1537
966248levothyroxine sodium 112 MCG Oral TabletPSN1537
966224levothyroxine sodium 125 MCG Oral TabletPSN1537
966270levothyroxine sodium 137 MCG Oral TabletPSN1537
966225levothyroxine sodium 150 MCG Oral TabletPSN1537
966249levothyroxine sodium 175 MCG Oral TabletPSN1537
892251levothyroxine sodium 200 MCG Oral TabletPSN1537
966220levothyroxine sodium 25 MCG Oral TabletPSN1537
892255levothyroxine sodium 300 MCG Oral TabletPSN1537
966221levothyroxine sodium 50 MCG Oral TabletPSN1537
966222levothyroxine sodium 75 MCG Oral TabletPSN1537
966253levothyroxine sodium 88 MCG Oral TabletPSN1537
966250SYNTHROID 100 MCG Oral TabletPSN1537
966185SYNTHROID 112 MCG Oral TabletPSN1537
966191SYNTHROID 125 MCG Oral TabletPSN1537
966271SYNTHROID 137 MCG Oral TabletPSN1537
966201SYNTHROID 150 MCG Oral TabletPSN1537
966205SYNTHROID 175 MCG Oral TabletPSN1537
966251SYNTHROID 200 MCG Oral TabletPSN1537
966158SYNTHROID 25 MCG Oral TabletPSN1537
966218SYNTHROID 300 MCG Oral TabletPSN1537
966247SYNTHROID 50 MCG Oral TabletPSN1537
966171SYNTHROID 75 MCG Oral TabletPSN1537
966282SYNTHROID 88 MCG Oral TabletPSN1537
966158levothyroxine sodium 0.025 MG Oral Tablet [Synthroid]SBD1537
966247levothyroxine sodium 0.05 MG Oral Tablet [Synthroid]SBD1537
966171levothyroxine sodium 0.075 MG Oral Tablet [Synthroid]SBD1537
966282levothyroxine sodium 0.088 MG Oral Tablet [Synthroid]SBD1537
966250levothyroxine sodium 0.1 MG Oral Tablet [Synthroid]SBD1537
966185levothyroxine sodium 0.112 MG Oral Tablet [Synthroid]SBD1537
966191levothyroxine sodium 0.125 MG Oral Tablet [Synthroid]SBD1537
966271levothyroxine sodium 0.137 MG Oral Tablet [Synthroid]SBD1537
966201levothyroxine sodium 0.15 MG Oral Tablet [Synthroid]SBD1537
966205levothyroxine sodium 0.175 MG Oral Tablet [Synthroid]SBD1537
966251levothyroxine sodium 0.2 MG Oral Tablet [Synthroid]SBD1537
966218levothyroxine sodium 0.3 MG Oral Tablet [Synthroid]SBD1537
966220levothyroxine sodium 0.025 MG Oral TabletSCD1537
966221levothyroxine sodium 0.05 MG Oral TabletSCD1537
966222levothyroxine sodium 0.075 MG Oral TabletSCD1537
966253levothyroxine sodium 0.088 MG Oral TabletSCD1537
892246levothyroxine sodium 0.1 MG Oral TabletSCD1537
966248levothyroxine sodium 0.112 MG Oral TabletSCD1537
966224levothyroxine sodium 0.125 MG Oral TabletSCD1537
966270levothyroxine sodium 0.137 MG Oral TabletSCD1537
966225levothyroxine sodium 0.15 MG Oral TabletSCD1537
966249levothyroxine sodium 0.175 MG Oral TabletSCD1537
892251levothyroxine sodium 0.2 MG Oral TabletSCD1537
892255levothyroxine sodium 0.3 MG Oral TabletSCD1537
892246levothyroxine sodium 100 MCG Oral TabletSY1537
966248levothyroxine sodium 112 MCG Oral TabletSY1537
966224levothyroxine sodium 125 MCG Oral TabletSY1537
966270levothyroxine sodium 137 MCG Oral TabletSY1537
966225levothyroxine sodium 150 MCG Oral TabletSY1537
966249levothyroxine sodium 175 MCG Oral TabletSY1537
892251levothyroxine sodium 200 MCG Oral TabletSY1537
966220levothyroxine sodium 25 MCG Oral TabletSY1537
892255levothyroxine sodium 300 MCG Oral TabletSY1537
966221levothyroxine sodium 50 MCG Oral TabletSY1537
966222levothyroxine sodium 75 MCG Oral TabletSY1537
966253levothyroxine sodium 88 MCG Oral TabletSY1537
966158Synthroid 0.025 MG Oral TabletSY1537
966247Synthroid 0.05 MG Oral TabletSY1537
966171Synthroid 0.075 MG Oral TabletSY1537
966282Synthroid 0.088 MG Oral TabletSY1537
966250Synthroid 0.1 MG Oral TabletSY1537
966185Synthroid 0.112 MG Oral TabletSY1537
966191Synthroid 0.125 MG Oral TabletSY1537
966271Synthroid 0.137 MG Oral TabletSY1537
966201Synthroid 0.15 MG Oral TabletSY1537
966205Synthroid 0.175 MG Oral TabletSY1537
966251Synthroid 0.2 MG Oral TabletSY1537
966218Synthroid 0.3 MG Oral TabletSY1537
966250Synthroid 100 MCG Oral TabletSY1537
966185Synthroid 112 MCG Oral TabletSY1537
966191Synthroid 125 MCG Oral TabletSY1537
966271Synthroid 137 MCG Oral TabletSY1537
966201Synthroid 150 MCG Oral TabletSY1537
966205Synthroid 175 MCG Oral TabletSY1537
966251Synthroid 200 MCG Oral TabletSY1537
966158Synthroid 25 MCG Oral TabletSY1537

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
LEVOTHYROXINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
97c252d3-9bb8-4530-bb44-9824dc7cf556Product name620250729
6c43b71c-35e6-4db3-ba24-c6ef42ff7003Product name320240207
890fd4bf-1a80-42b7-be1b-2d0259d5f0c8Product name520240207
c8ad26bf-af73-460b-b74e-1eff16cc4f9fProduct name520240207
594e2c86-3079-4e6e-96c9-48f7a8afc78dProduct name120230718
01383843-4069-43cf-aa76-dc17a6f9f8c4Product name220230123
978cca7d-a938-4791-8322-da48d90a63efProduct name120230113
65f86ba3-8816-4e12-899b-18290c8de551Product name220210614
f16ab90f-08c2-40be-a543-66d9827cd1f3Product name120210601
6a33ec05-2ae2-45e5-ab82-2d94b3303923Product name120190709
93355a10-1c44-4c92-a11d-7d995e0200d9Product name120190219

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0074-3727-13Synthroid100 in 1 BOTTLETABLET1001537
0074-3727-19Synthroid1000 in 1 BOTTLETABLET10001537
0074-3727-71Synthroid4 in 1 CARTONTABLET41537
0074-3727-71Synthroid7 in 1 BLISTER PACKTABLET71537
0074-3727-72Synthroid2 in 1 CARTONTABLET21537
0074-3727-72Synthroid7 in 1 BLISTER PACKTABLET71537
0074-3727-90Synthroid90 in 1 BOTTLETABLET901537
0074-4341-13Synthroid100 in 1 BOTTLETABLET1001537
0074-4341-19Synthroid1000 in 1 BOTTLETABLET10001537
0074-4341-72Synthroid7 in 1 BLISTER PACKTABLET71537
0074-4341-72Synthroid2 in 1 CARTONTABLET21537
0074-4341-90Synthroid90 in 1 BOTTLETABLET901537
0074-4552-11Synthroid10 in 1 BLISTER PACKTABLET101537
0074-4552-11Synthroid10 in 1 BOX, UNIT-DOSETABLET101537
0074-4552-13Synthroid100 in 1 BOTTLETABLET1001537
0074-4552-19Synthroid1000 in 1 BOTTLETABLET10001537
0074-4552-71Synthroid7 in 1 BLISTER PACKTABLET71537
0074-4552-71Synthroid4 in 1 CARTONTABLET41537
0074-4552-72Synthroid2 in 1 CARTONTABLET21537
0074-4552-72Synthroid7 in 1 BLISTER PACKTABLET71537
0074-4552-90Synthroid90 in 1 BOTTLETABLET901537
0074-5182-11Synthroid10 in 1 BLISTER PACKTABLET101537
0074-5182-11Synthroid10 in 1 BOX, UNIT-DOSETABLET101537
0074-5182-13Synthroid100 in 1 BOTTLETABLET1001537
0074-5182-19Synthroid1000 in 1 BOTTLETABLET10001537
0074-5182-71Synthroid7 in 1 BLISTER PACKTABLET71537
0074-5182-71Synthroid4 in 1 CARTONTABLET41537
0074-5182-72Synthroid7 in 1 BLISTER PACKTABLET71537
0074-5182-72Synthroid2 in 1 CARTONTABLET21537
0074-5182-90Synthroid90 in 1 BOTTLETABLET901537
0074-6594-13Synthroid100 in 1 BOTTLETABLET1001537
0074-6594-19Synthroid1000 in 1 BOTTLETABLET10001537
0074-6594-71Synthroid4 in 1 CARTONTABLET41537
0074-6594-71Synthroid7 in 1 BLISTER PACKTABLET71537
0074-6594-72Synthroid7 in 1 BLISTER PACKTABLET71537
0074-6594-72Synthroid2 in 1 CARTONTABLET21537
0074-6594-90Synthroid90 in 1 BOTTLETABLET901537
0074-6624-11Synthroid10 in 1 BOX, UNIT-DOSETABLET101537
0074-6624-11Synthroid10 in 1 BLISTER PACKTABLET101537
0074-6624-13Synthroid100 in 1 BOTTLETABLET1001537
0074-6624-19Synthroid1000 in 1 BOTTLETABLET10001537
0074-6624-71Synthroid4 in 1 CARTONTABLET41537
0074-6624-71Synthroid7 in 1 BLISTER PACKTABLET71537
0074-6624-72Synthroid2 in 1 CARTONTABLET21537
0074-6624-72Synthroid7 in 1 BLISTER PACKTABLET71537
0074-6624-90Synthroid90 in 1 BOTTLETABLET901537
0074-7068-11Synthroid10 in 1 BLISTER PACKTABLET101537
0074-7068-11Synthroid10 in 1 BOX, UNIT-DOSETABLET101537
0074-7068-13Synthroid100 in 1 BOTTLETABLET1001537
0074-7068-19Synthroid1000 in 1 BOTTLETABLET10001537
0074-7068-71Synthroid4 in 1 CARTONTABLET41537
0074-7068-71Synthroid7 in 1 BLISTER PACKTABLET71537
0074-7068-72Synthroid7 in 1 BLISTER PACKTABLET71537
0074-7068-72Synthroid2 in 1 CARTONTABLET21537
0074-7068-90Synthroid90 in 1 BOTTLETABLET901537
0074-7069-11Synthroid10 in 1 BLISTER PACKTABLET101537
0074-7069-11Synthroid10 in 1 BOX, UNIT-DOSETABLET101537
0074-7069-19Synthroid1000 in 1 BOTTLETABLET10001537
0074-7069-71Synthroid4 in 1 CARTONTABLET41537
0074-7069-71Synthroid7 in 1 BLISTER PACKTABLET71537
0074-7069-72Synthroid2 in 1 CARTONTABLET21537
0074-7069-72Synthroid7 in 1 BLISTER PACKTABLET71537
0074-7069-90Synthroid90 in 1 BOTTLETABLET901537
0074-7070-13Synthroid100 in 1 BOTTLETABLET1001537
0074-7070-19Synthroid1000 in 1 BOTTLETABLET10001537
0074-7070-71Synthroid7 in 1 BLISTER PACKTABLET71537
0074-7070-71Synthroid4 in 1 CARTONTABLET41537
0074-7070-72Synthroid2 in 1 CARTONTABLET21537
0074-7070-72Synthroid7 in 1 BLISTER PACKTABLET71537
0074-7070-90Synthroid90 in 1 BOTTLETABLET901537
0074-7148-11Synthroid10 in 1 BOX, UNIT-DOSETABLET101537
0074-7148-11Synthroid10 in 1 BLISTER PACKTABLET101537
0074-7148-19Synthroid1000 in 1 BOTTLETABLET10001537
0074-7148-71Synthroid7 in 1 BLISTER PACKTABLET71537
0074-7148-71Synthroid4 in 1 CARTONTABLET41537
0074-7148-72Synthroid2 in 1 CARTONTABLET21537
0074-7148-72Synthroid7 in 1 BLISTER PACKTABLET71537
0074-7148-90Synthroid90 in 1 BOTTLETABLET901537
0074-7149-19Synthroid1000 in 1 BOTTLETABLET10001537
0074-7149-90Synthroid90 in 1 BOTTLETABLET901537
0074-9296-13Synthroid100 in 1 BOTTLETABLET1001537
0074-9296-19Synthroid1000 in 1 BOTTLETABLET10001537
0074-9296-71Synthroid4 in 1 CARTONTABLET41537
0074-9296-71Synthroid7 in 1 BLISTER PACKTABLET71537
0074-9296-72Synthroid7 in 1 BLISTER PACKTABLET71537
0074-9296-72Synthroid2 in 1 CARTONTABLET21537
0074-9296-90Synthroid90 in 1 BOTTLETABLET901537

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0074-3727SYNTHROID (LEVOTHYROXINE SODIUM) TABLET [ABBVIE INC.]1537Current NDC, Legacy NDC, 7 package rows20240229_1e11ad30-1041-4520-10b0-8f9d30d30fcc.zip
0074-4341SYNTHROID (LEVOTHYROXINE SODIUM) TABLET [ABBVIE INC.]1537Current NDC, Legacy NDC, 5 package rows20240229_1e11ad30-1041-4520-10b0-8f9d30d30fcc.zip
0074-4552SYNTHROID (LEVOTHYROXINE SODIUM) TABLET [ABBVIE INC.]1537Current NDC, Legacy NDC, 9 package rows20240229_1e11ad30-1041-4520-10b0-8f9d30d30fcc.zip
0074-5182SYNTHROID (LEVOTHYROXINE SODIUM) TABLET [ABBVIE INC.]1537Current NDC, Legacy NDC, 9 package rows20240229_1e11ad30-1041-4520-10b0-8f9d30d30fcc.zip
0074-6594SYNTHROID (LEVOTHYROXINE SODIUM) TABLET [ABBVIE INC.]1537Current NDC, Legacy NDC, 7 package rows20240229_1e11ad30-1041-4520-10b0-8f9d30d30fcc.zip
0074-6624SYNTHROID (LEVOTHYROXINE SODIUM) TABLET [ABBVIE INC.]1537Current NDC, Legacy NDC, 9 package rows20240229_1e11ad30-1041-4520-10b0-8f9d30d30fcc.zip
0074-7068SYNTHROID (LEVOTHYROXINE SODIUM) TABLET [ABBVIE INC.]1537Current NDC, Legacy NDC, 9 package rows20240229_1e11ad30-1041-4520-10b0-8f9d30d30fcc.zip
0074-7069SYNTHROID (LEVOTHYROXINE SODIUM) TABLET [ABBVIE INC.]1537Current NDC, Legacy NDC, 8 package rows20240229_1e11ad30-1041-4520-10b0-8f9d30d30fcc.zip
0074-7070SYNTHROID (LEVOTHYROXINE SODIUM) TABLET [ABBVIE INC.]1537Current NDC, Legacy NDC, 7 package rows20240229_1e11ad30-1041-4520-10b0-8f9d30d30fcc.zip
0074-7148SYNTHROID (LEVOTHYROXINE SODIUM) TABLET [ABBVIE INC.]1537Current NDC, Legacy NDC, 8 package rows20240229_1e11ad30-1041-4520-10b0-8f9d30d30fcc.zip
0074-7149SYNTHROID (LEVOTHYROXINE SODIUM) TABLET [ABBVIE INC.]1537Current NDC, Legacy NDC, 2 package rows20240229_1e11ad30-1041-4520-10b0-8f9d30d30fcc.zip
0074-9296SYNTHROID (LEVOTHYROXINE SODIUM) TABLET [ABBVIE INC.]1537Current NDC, Legacy NDC, 7 package rows20240229_1e11ad30-1041-4520-10b0-8f9d30d30fcc.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0074-4341-19EA - Each0074-4341e7317b8a-4628-4ef9-9343-d42e31f5c47d12012-07-24
0074-4341-90EA - Each0074-4341506319f1-923c-4dc1-be0c-d18692835b3c12012-07-24
0074-4552-11EA - Each0074-455240bb59e2-b251-43fd-83bc-b3c11b6153b012012-07-24
0074-4552-19EA - Each0074-45523104fc37-97a6-436a-b86f-0aa5dc164b1612012-07-24
0074-4552-90EA - Each0074-4552f3096f40-42a7-4d1d-9f88-d11329b3c56512012-07-24
0074-5182-11EA - Each0074-51820dce4e2f-213e-437a-9922-58d415f5d25b12012-07-24
0074-5182-19EA - Each0074-518229fe94b8-01e0-4a47-a266-7841414dd5b512012-07-24
0074-5182-90EA - Each0074-51827a168286-6bf0-47b1-99a8-2466bf6c2a9112012-07-24
0074-6594-19EA - Each0074-6594b302b20f-44b4-44ff-9fa6-ac3f1a10314712012-07-24
0074-6594-90EA - Each0074-6594d8abd66f-5199-4989-89e2-2fe4f779faea12012-07-24
0074-6624-11EA - Each0074-66245f76f9ce-da99-47b3-9072-8dbe177b7cf212012-07-24
0074-6624-19EA - Each0074-6624cc18465b-ed0b-470d-b9a3-240db7e9adaf12012-07-24
0074-6624-90EA - Each0074-6624d2d3c1a5-61ab-49b8-907a-3742aae3f14a12012-07-24
0074-9296-19EA - Each0074-929680b3a816-b2b4-44e6-a7a1-2f0602db1b2b12012-07-24
0074-9296-90EA - Each0074-929637f76960-9107-47c0-920e-c65792078b7112012-07-24
0074-7068-11EA - Each0074-70684f6c240f-3316-46fe-b5d0-2a48ad44c17d12012-07-24
0074-7068-19EA - Each0074-706881be8390-fa97-4afb-b6a1-52bdebf8d58e12012-07-24
0074-7068-90EA - Each0074-7068fc30f360-861a-4f5c-8d04-d8c82c7b52b912012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
LEVOTHYROXINE SODIUMACTIVE INGREDIENT9J765S329G1492
LEVOTHYROXINEACTIVE MOIETYQ51BO43MG41492
ACACIAINACTIVE INGREDIENT5C5403N26O1492
D&C RED NO. 27INACTIVE INGREDIENT2LRS185U6K1492
D&C RED NO. 30INACTIVE INGREDIENT2S42T2808B1492
D&C YELLOW NO. 10INACTIVE INGREDIENT35SW5USQ3G1492
FD&C BLUE NO. 1INACTIVE INGREDIENTH3R47K3TBD1492
FD&C BLUE NO. 2INACTIVE INGREDIENTL06K8R7DQK1492
FD&C RED NO. 40INACTIVE INGREDIENTWZB9127XOA1492
FD&C YELLOW NO. 6INACTIVE INGREDIENTH77VEI93A81492
LACTOSE MONOHYDRATEINACTIVE INGREDIENTEWQ57Q8I5X1492
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I301492
POVIDONESINACTIVE INGREDIENTFZ989GH94E1492
SUCROSEINACTIVE INGREDIENTC151H8M5541492
TALCINACTIVE INGREDIENT7SEV7J4R1U1492

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 17 matching rows.

NDC Codes#

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 3 · 106 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 16 · 936 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
D&C RED NO. 30D&C RED NO. 302S42T2808BTABLET / ORAL19 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOATABLET / ORAL4 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
D&C RED NO. 30D&C RED NO. 302S42T2808BTABLET / ORAL19 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 2FD&C BLUE NO. 2L06K8R7DQKTABLET / ORAL25 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOATABLET / ORAL4 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 2FD&C BLUE NO. 2L06K8R7DQKTABLET / ORAL25 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XTABLET / ORAL4384 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 2FD&C BLUE NO. 2L06K8R7DQKTABLET / ORAL25 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
POVIDONESPOVIDONEFZ989GH94ETABLET / ORAL216 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GTABLET / ORAL80 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
ACACIAACACIA5C5403N26OTABLET / ORAL70 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
D&C RED NO. 27D&C RED NO. 272LRS185U6KTABLET / ORAL1 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
ACACIAACACIA5C5403N26OTABLET / ORAL70 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
D&C RED NO. 30D&C RED NO. 302S42T2808BTABLET / ORAL19 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GTABLET / ORAL80 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
D&C RED NO. 27D&C RED NO. 272LRS185U6KTABLET / ORAL1 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET / ORAL4249 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET / ORAL1000 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOATABLET / ORAL4 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
D&C RED NO. 30D&C RED NO. 302S42T2808BTABLET / ORAL19 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
D&C RED NO. 27D&C RED NO. 272LRS185U6KTABLET / ORAL1 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
D&C RED NO. 30D&C RED NO. 302S42T2808BTABLET / ORAL19 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDTABLET / ORAL27.53 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
D&C RED NO. 30D&C RED NO. 302S42T2808BTABLET / ORAL19 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 2FD&C BLUE NO. 2L06K8R7DQKTABLET / ORAL25 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDTABLET / ORAL27.53 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
POVIDONESPOVIDONEFZ989GH94ETABLET / ORAL216 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET / ORAL4249 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET / ORAL4249 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
ACACIAACACIA5C5403N26OTABLET / ORAL70 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOATABLET / ORAL4 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 2FD&C BLUE NO. 2L06K8R7DQKTABLET / ORAL25 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
TALCTALC7SEV7J4R1UTABLET / ORAL1000 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 2FD&C BLUE NO. 2L06K8R7DQKTABLET / ORAL25 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
ACACIAACACIA5C5403N26OTABLET / ORAL70 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET / ORAL4249 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOATABLET / ORAL4 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
POVIDONESPOVIDONEFZ989GH94ETABLET / ORAL216 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XTABLET / ORAL4384 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
ACACIAACACIA5C5403N26OTABLET / ORAL70 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOATABLET / ORAL4 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C YELLOW NO. 6FD&C YELLOW NO. 6H77VEI93A8TABLET / ORAL60.02 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C YELLOW NO. 6FD&C YELLOW NO. 6H77VEI93A8TABLET / ORAL60.02 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET / ORAL4249 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOATABLET / ORAL4 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOATABLET / ORAL4 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDTABLET / ORAL27.53 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
D&C RED NO. 27D&C RED NO. 272LRS185U6KTABLET / ORAL1 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
POVIDONESPOVIDONEFZ989GH94ETABLET / ORAL216 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDTABLET / ORAL27.53 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
SUCROSESUCROSEC151H8M554TABLET / ORAL4249 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDTABLET / ORAL27.53 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 2FD&C BLUE NO. 2L06K8R7DQKTABLET / ORAL25 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
ACACIAACACIA5C5403N26OTABLET / ORAL70 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDTABLET / ORAL27.53 mgExact identifier — unii+route+dosage form
72 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 12 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N021402-001SYNTHROIDLEVOTHYROXINE SODIUM0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24
N021402-002SYNTHROIDLEVOTHYROXINE SODIUM0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24
N021402-003SYNTHROIDLEVOTHYROXINE SODIUM0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24
N021402-004SYNTHROIDLEVOTHYROXINE SODIUM0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24
N021402-005SYNTHROIDLEVOTHYROXINE SODIUM0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24
N021402-006SYNTHROIDLEVOTHYROXINE SODIUM0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24
N021402-007SYNTHROIDLEVOTHYROXINE SODIUM0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24
N021402-008SYNTHROIDLEVOTHYROXINE SODIUM0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24
N021402-009SYNTHROIDLEVOTHYROXINE SODIUM0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24
N021402-010SYNTHROIDLEVOTHYROXINE SODIUM0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24
N021402-011SYNTHROIDLEVOTHYROXINE SODIUM0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD, RS2002-07-24
N021402-012SYNTHROIDLEVOTHYROXINE SODIUM0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 24 matching rows.

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 14 · 540 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N021402-001SYNTHROID0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-002SYNTHROID0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-003SYNTHROID0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-004SYNTHROID0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-005SYNTHROID0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-006SYNTHROID0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-007SYNTHROID0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-008SYNTHROID0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-009SYNTHROID0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-010SYNTHROID0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-011SYNTHROID0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD, RS2002-07-24d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-012SYNTHROID0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24d4dbc9d85df4…
2026-10-15 13:18:302026-09N021402-001SYNTHROID0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24c2088c7a36db…
2026-10-15 13:18:302026-09N021402-002SYNTHROID0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24c2088c7a36db…
2026-10-15 13:18:302026-09N021402-003SYNTHROID0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24c2088c7a36db…
2026-10-15 13:18:302026-09N021402-004SYNTHROID0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24c2088c7a36db…
2026-10-15 13:18:302026-09N021402-005SYNTHROID0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24c2088c7a36db…
2026-10-15 13:18:302026-09N021402-006SYNTHROID0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24c2088c7a36db…
2026-10-15 13:18:302026-09N021402-007SYNTHROID0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24c2088c7a36db…
2026-10-15 13:18:302026-09N021402-008SYNTHROID0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24c2088c7a36db…
2026-10-15 13:18:302026-09N021402-009SYNTHROID0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24c2088c7a36db…
2026-10-15 13:18:302026-09N021402-010SYNTHROID0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24c2088c7a36db…
2026-10-15 13:18:302026-09N021402-011SYNTHROID0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD, RS2002-07-24c2088c7a36db…
2026-10-15 13:18:302026-09N021402-012SYNTHROID0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24c2088c7a36db…
2026-09-14 22:38:342026-08N021402-001SYNTHROID0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-2484e616aacf4f…
2026-09-14 22:38:342026-08N021402-002SYNTHROID0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-2484e616aacf4f…
2026-09-14 22:38:342026-08N021402-003SYNTHROID0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-2484e616aacf4f…
2026-09-14 22:38:342026-08N021402-004SYNTHROID0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-2484e616aacf4f…
2026-09-14 22:38:342026-08N021402-005SYNTHROID0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-2484e616aacf4f…
2026-09-14 22:38:342026-08N021402-006SYNTHROID0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-2484e616aacf4f…
2026-09-14 22:38:342026-08N021402-007SYNTHROID0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-2484e616aacf4f…
2026-09-14 22:38:342026-08N021402-008SYNTHROID0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-2484e616aacf4f…
2026-09-14 22:38:342026-08N021402-009SYNTHROID0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-2484e616aacf4f…
2026-09-14 22:38:342026-08N021402-010SYNTHROID0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-2484e616aacf4f…
2026-09-14 22:38:342026-08N021402-011SYNTHROID0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD, RS2002-07-2484e616aacf4f…
2026-09-14 22:38:342026-08N021402-012SYNTHROID0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-2484e616aacf4f…
2026-08-18 06:07:402026-07N021402-001SYNTHROID0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24caaa826d4ba7…
2026-08-18 06:07:402026-07N021402-002SYNTHROID0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24caaa826d4ba7…
2026-08-18 06:07:402026-07N021402-003SYNTHROID0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24caaa826d4ba7…
2026-08-18 06:07:402026-07N021402-004SYNTHROID0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine SodiumTABLET / ORALAB1,AB2RLD2002-07-24caaa826d4ba7…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 27 · 1,080 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10N021402-001AB11d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-001AB22d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-002AB11d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-002AB22d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-003AB11d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-003AB22d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-004AB11d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-004AB22d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-005AB11d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-005AB22d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-006AB11d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-006AB22d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-007AB11d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-007AB22d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-008AB11d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-008AB22d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-009AB11d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-009AB22d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-010AB11d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-010AB22d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-011AB11d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-011AB22d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-012AB11d4dbc9d85df4…
2026-11-14 07:37:172026-10N021402-012AB22d4dbc9d85df4…
2026-10-15 13:18:302026-09N021402-001AB11c2088c7a36db…
2026-10-15 13:18:302026-09N021402-001AB22c2088c7a36db…
2026-10-15 13:18:302026-09N021402-002AB11c2088c7a36db…
2026-10-15 13:18:302026-09N021402-002AB22c2088c7a36db…
2026-10-15 13:18:302026-09N021402-003AB11c2088c7a36db…
2026-10-15 13:18:302026-09N021402-003AB22c2088c7a36db…
2026-10-15 13:18:302026-09N021402-004AB11c2088c7a36db…
2026-10-15 13:18:302026-09N021402-004AB22c2088c7a36db…
2026-10-15 13:18:302026-09N021402-005AB11c2088c7a36db…
2026-10-15 13:18:302026-09N021402-005AB22c2088c7a36db…
2026-10-15 13:18:302026-09N021402-006AB11c2088c7a36db…
2026-10-15 13:18:302026-09N021402-006AB22c2088c7a36db…
2026-10-15 13:18:302026-09N021402-007AB11c2088c7a36db…
2026-10-15 13:18:302026-09N021402-007AB22c2088c7a36db…
2026-10-15 13:18:302026-09N021402-008AB11c2088c7a36db…
2026-10-15 13:18:302026-09N021402-008AB22c2088c7a36db…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
SynthroidLEVOTHYROXINE SODIUMAbbVie Inc.1e11ad30-1041-4520-10b0-8f9d30d30fcc2024-02-20Boxed warning, Warnings, Adverse reactionsExact identifier
ndc (package): 0074-5182-72
ndc (package): 0074-4552-71
ndc (package): 0074-4552-72
ndc (package): 0074-6594-90
ndc (package): 0074-9296-72
ndc (package): 0074-7070-90
ndc (package): 0074-3727-13
ndc (package): 0074-7069-71
ndc (package): 0074-5182-13
ndc (package): 0074-7149-90
ndc (package): 0074-4341-13
ndc (package): 0074-7070-19
ndc (package): 0074-7069-72
ndc (package): 0074-6594-13
ndc (package): 0074-9296-71
ndc (package): 0074-6624-72
ndc (package): 0074-3727-72
ndc (package): 0074-7069-11
ndc (package): 0074-7070-72
ndc (package): 0074-5182-11
ndc (package): 0074-7148-19
ndc (package): 0074-6594-72
ndc (package): 0074-3727-90
ndc (package): 0074-7148-72
ndc (package): 0074-7068-72
ndc (package): 0074-9296-19
ndc (package): 0074-3727-19
ndc (package): 0074-7148-11
ndc (package): 0074-7068-90
ndc (package): 0074-7070-13
ndc (package): 0074-7148-71
ndc (package): 0074-5182-71
ndc (package): 0074-6624-19
ndc (package): 0074-4552-90
ndc (package): 0074-7068-71
ndc (package): 0074-7070-71
ndc (package): 0074-6624-11
ndc (package): 0074-6624-71
ndc (package): 0074-7069-90
ndc (package): 0074-7149-19
ndc (package): 0074-4552-11
ndc (package): 0074-6594-19
ndc (package): 0074-7068-13
ndc (package): 0074-9296-90
ndc (package): 0074-4341-19
ndc (package): 0074-4552-13
ndc (package): 0074-9296-13
ndc (package): 0074-5182-90
ndc (package): 0074-5182-19
ndc (package): 0074-7068-19
ndc (package): 0074-7068-11
ndc (package): 0074-6594-71
ndc (package): 0074-4341-90
ndc (package): 0074-6624-90
ndc (package): 0074-7069-19
ndc (package): 0074-4341-72
ndc (package): 0074-6624-13
ndc (package): 0074-4552-19
ndc (package): 0074-7148-90
ndc (package): 0074-3727-71
ndc (product): 0074-7070
ndc (product): 0074-7149
ndc (product): 0074-4341
ndc (product): 0074-4552
ndc (product): 0074-7148
ndc (product): 0074-6594
ndc (product): 0074-3727
ndc (product): 0074-5182
ndc (product): 0074-7068
ndc (product): 0074-9296
ndc (product): 0074-6624
ndc (product): 0074-7069
ndc11 (package): 00074714919
ndc11 (package): 00074434113
ndc11 (package): 00074455271
ndc11 (package): 00074455290
ndc11 (package): 00074434190
ndc11 (package): 00074714990
ndc11 (package): 00074714819
ndc11 (package): 00074372713
ndc11 (package): 00074706813
ndc11 (package): 00074518219
ndc11 (package): 00074518271
ndc11 (package): 00074714890
ndc11 (package): 00074706919
ndc11 (package): 00074455213
ndc11 (package): 00074929672
ndc11 (package): 00074929619
ndc11 (package): 00074518213
ndc11 (package): 00074706890
ndc11 (package): 00074706871
ndc11 (package): 00074659419
ndc11 (package): 00074434119
ndc11 (package): 00074706872
ndc11 (package): 00074455219
ndc11 (package): 00074455211
ndc11 (package): 00074518211
ndc11 (package): 00074707071
ndc11 (package): 00074714811
ndc11 (package): 00074662411
ndc11 (package): 00074662413
ndc11 (package): 00074707072
ndc11 (package): 00074707019
ndc11 (package): 00074706911
ndc11 (package): 00074659413
ndc11 (package): 00074434172
ndc11 (package): 00074929613
ndc11 (package): 00074929671
ndc11 (package): 00074714871
ndc11 (package): 00074518272
ndc11 (package): 00074372790
ndc11 (package): 00074372771
ndc11 (package): 00074706972
ndc11 (package): 00074929690
ndc11 (package): 00074372719
ndc11 (package): 00074455272
ndc11 (package): 00074706811
ndc11 (package): 00074707090
ndc11 (package): 00074707013
ndc11 (package): 00074706971
ndc11 (package): 00074518290
ndc11 (package): 00074662419
ndc11 (package): 00074706990
ndc11 (package): 00074659471
ndc11 (package): 00074662490
ndc11 (package): 00074659490
ndc11 (package): 00074659472
ndc11 (package): 00074662472
ndc11 (package): 00074372772
ndc11 (package): 00074662471
ndc11 (package): 00074714872
ndc11 (package): 00074706819
spl id: b85ab7fa-ba96-43cd-b736-44b3924e644c
spl set id: 1e11ad30-1041-4520-10b0-8f9d30d30fcc

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.